(191 days)
Not Found
No
The 510(k) summary describes a synthetic bone graft putty and its performance testing, with no mention of AI or ML technology in its description, intended use, or performance studies.
Yes
The device is a bone void filler intended for use in bony voids or gaps of the skeletal system to facilitate bone healing, indicating its therapeutic purpose.
No
Explanation: This device is a bone void filler intended for use in bony voids or gaps; it is a therapeutic device, not a diagnostic one.
No
The device is a physical bone graft putty, not software. The description details its composition, form, and packaging, all of which are hardware components.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states the device is a "bone void filler device intended for use in bony voids or gaps...". This describes a device used in vivo (within the body) to fill physical defects.
- Device Description: The description details the composition of the putty and how it's supplied for surgical use. This aligns with a medical device used during a procedure.
- Lack of IVD Characteristics: There is no mention of the device being used to test samples in vitro (outside the body), such as blood, urine, or tissue, to diagnose a condition or monitor health.
IVD devices are used to perform tests on samples taken from the body to provide information about a person's health. This device is a therapeutic device used to physically repair bone defects within the body.
N/A
Intended Use / Indications for Use
Bioactive Bone Graft Putty is a bone void filler device intended for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. Bioactive Bone Graft Putty is indicated to be packed gently into bony voids or gaps of the skeletal system (i.e., extremities, pelvis and posterolateral spine fusion procedures). Bioactive Bone Graft Putty can also be used with autograft as a bone graft extender in the posterolateral spine. The device provides a bone void filler that is resorbed and replaced with host bone during the healing process.
Product codes
MQV
Device Description
Bioactive Bone Graft Putty is a synthetic bone void filler comprised of a mixture of calcium phosphate granules and bioactive glass granules suspended in a resorbable polymer carrier that facilitates handling and delivery of the granule components. The device is supplied as putty, pre-loaded in a syringe applicator and packaged in a sterile barrier foil pouch. The device is provided sterile, for single use, in a variety of sizes.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
skeletal system (i.e., extremities, pelvis and posterolateral spine fusion procedures)
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Non-clinical testing was performed in accordance with FDA recognized consensus standards and FDA guidance documents as applicable.
Raw materials characterization testing was performed according to ASTM standards: F1538-03, F1185-03, F1088-04a, F1929/F1926M and USP NF.
Biocompatibility testing, according to ISO 10993 for a long-term implant product. demonstrated the device is biocompatible and non-toxic.
Packaging, sterilization and shelf life testing according to the following standards were presented in the 510(k):
- Packaging: ISO11607, ASTM F2096-11, F88-09 and . F1929-98; and ISO 11137.
- Sterilization and Shelf Life; ISO 11137 and ASTM F1980.
The device is considered bioactive based on in vitro studies that show apatite laver formation on the surface of the implant following immersion in simulated body fluid (SBF). These results have not been correlated to clinical performance.
Animal performance testing was performed in femoral cancellous defect and posterolateral spine fusion (PLF) rabbit models to evaluate the safety and performance of the Bioactive Bone Graft Putty compared to a predicate device. The test results showed equivalent in vivo performance in safety, graft resorption and new bone formation.
Key Metrics
Not Found
Predicate Device(s)
K071206, K043005, K112857, K020078
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 888.3045 Resorbable calcium salt bone void filler device.
(a)
Identification. A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.
0
K 132071
Page 1 of 2
Submitter:
BioStructures, LLC
Bioactive Bone Graft Putty
510(k) SUMMARY
| Submitter Name: | BioStructures, LLC |
|---|---|
| Submitter Address: | 1201 Dove Street, Suite 470 |
| Newport Beach, CA 92660 | |
| JAN 10 2014 | |
| Contact Person: | John Brunelle, Ph.D. |
| Director of R&D/ Manufacturing | |
| Phone Number: | 949.553.1717 |
| Date Prepared: | July 2, 2013 |
| Device Trade Name: | Bioactive Bone Graft Putty |
| Device Classification: | Class II |
| Classification Name: | Filler, Bone Void, Calcium Compound |
| Classification Number: | 21 CFR 888.3045 |
| Product Code: | MQV |
| Predicate Device(s): | K071206, Actifuse® ABX, ApaTech Limited |
| K043005, MBCP™™, Biomatlante | |
| K112857, Interface Bone Void Filler, BioStructures, LLC | |
| K020078, Exactech Resorbable Bone Paste, Exactech, Inc. | |
| Indications for Use | |
| Statement: | Bioactive Bone Graft Putty is a bone void filler device intended for |
| use in bony voids or gaps that are not intrinsic to the stability of | |
| the bony structure. These defects may be surgically created | |
| osseous defects or osseous defects created from traumatic injury | |
| to the bone. Bioactive Bone Graft Putty is indicated to be packed | |
| gently into bony voids or gaps of the skeletal system (i.e., | |
| extremities, pelvis and posterolateral spine fusion procedures). | |
| Bioactive Bone Graft Putty can also be used with autograft as a | |
| bone graft extender in the posterolateral spine. The device | |
| provides a bone void filler that is resorbed and replaced with host | |
| bone during the healing process. | |
| Device Description: | Bioactive Bone Graft Putty is a synthetic bone void filler comprised |
| of a mixture of calcium phosphate granules and bioactive glass | |
| granules suspended in a resorbable polymer carrier that facilitates | |
| handling and delivery of the granule components. The device is | |
| supplied as putty, pre-loaded in a syringe applicator and packaged | |
| in a sterile barrier foil pouch. The device is provided sterile, for | |
| single use, in a variety of sizes. | |
| Summary of Testing: | Non-clinical testing was performed in accordance with FDA |
| recognized consensus standards and FDA guidance documents | |
| as applicable. | |
| Raw materials characterization testing was performed according | |
| to ASTM standards: F1538-03, F1185-03, F1088-04a, | |
| F1929/F1926M and USP NF. |
.
1
| Submitter: | BioStructures, LLC | |
|---|---|---|
| ------------ | -------------------- | -- |
Bioactive Bone Graft Putty Traditional 510(k)
Biocompatibility testing, according to ISO 10993 for a long-term implant product. demonstrated the device is biocompatible and non-toxic.
Packaging, sterilization and shelf life testing according to the following standards were presented in the 510(k):
- Packaging: ISO11607, ASTM F2096-11, F88-09 and . F1929-98; and ISO 11137.
- Sterilization and Shelf Life; ISO 11137 and ASTM F1980. .
The device is considered bioactive based on in vitro studies that show apatite laver formation on the surface of the implant following immersion in simulated body fluid (SBF). These results have not been correlated to clinical performance.
Animal performance testing was performed in femoral cancellous defect and posterolateral spine fusion (PLF) rabbit models to evaluate the safety and performance of the Bioactive Bone Graft Putty compared to a predicate device. The test results showed equivalent in vivo performance in safety, graft resorption and new bone formation.
Bioactive Bone Graft Putty has the same intended use and the same principles of operation as all the predicates, which serve as osteoconductive matrices for new bone formation.
Bioactive Bone Graft Putty is similar technologically to the four predicates.
The technological differences presented by the composition of materials in Bioactive Bone Graft Putty do not raise new issues of safety or effectiveness, as demonstrated by the side-by-side evaluation in the animal performance studies.
The comparisons and study data presented in the 510(k) lead to the conclusion that Bioactive Bone Graft Putty is substantially equivalent to the predicate devices.
Comparison to the Predicate Devices:
Substantjal Equivalence Conclusion:
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized depiction of an eagle with three overlapping wings, representing health, services, and people. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged around the eagle symbol in a circular fashion.
Public Health Service
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
January 10, 2014
BioStructures, LLC % Patsy J. Trisler, JD, RAC Trisler Consulting 5600 Wisconsin Avenue #509 Chevy Chase, Maryland 20815
Re: K132071
Trade/Device Name: Bioactive Bone Graft Putty Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable calcium salt bone void filler device Regulatory Class: Class II Product Code: MOV Dated: December 2, 2013 Received: December 3, 2013
Dear Ms. Trisler:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28. 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
3
Page 2 - Patsy J. Trisler. JD, RAC
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers. International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours.
Ronalden - Jean - S for
Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
510(k) Number (if known):
Device Name:
Bioactive Bone Graft Puttv
Indications for Use:
Bioactive Bone Graft Putty is a bone void filler device intended for use in bony voids or gaps that are not intrinsic to the stability of the bony structure. These defects may be surgically created osseous defects or osseous defects created from traumatic injury to the bone. Bioactive Bone Graft Putty is indicated to be packed gently into bony voids or gaps of the skeletal system (i.e., extremities, pelvis and posterolateral spine fusion procedures). Bioactive Bone Graft Putty can also be used with autograft as a bone graft extender in the posterolateral spine. The device provides a bone void filler that is resorbed and replaced with host bone during the healing process.
Prescription Use X
AND/OR
Over-The-Counter Use
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Laurence D. Coyne -S
(Division Sign-Off) Division of Orthopedic Devices 510(k) Number: K132071
Section 4.0
Page 1 of 1